Last reviewed 2026-04-23 · How we verify

Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab

Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab is a PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently in Phase 3 development for Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive, Other cancers with PD-L1 expression.

Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents.

Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents. Used for Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive, Other cancers with PD-L1 expression.

At a glance

Mechanism of action

Socazolimab works by binding to PD-1 and blocking its interaction with PD-L1, thereby enhancing T-cell activation and proliferation. Bevacizumab inhibits angiogenesis by binding to VEGF. Paclitaxel stabilizes microtubules, preventing cell division, while cisplatin and carboplatin form platinum-DNA adducts, interfering with DNA replication and transcription.

Approved indications

• Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive
• Other cancers with PD-L1 expression

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Neutropenia
• Anemia
• Thrombocytopenia

Key clinical trials

• Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab CI brief — competitive landscape report
• Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab updates RSS · CI watch RSS
• Lee's Pharmaceutical Limited portfolio CI

Frequently asked questions about Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab

Related

• Drug class: All PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent drugs
• Target: All drugs targeting PD-1, VEGF, microtubules, DNA
• Manufacturer: Lee's Pharmaceutical Limited — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive
• Indication: Drugs for Other cancers with PD-L1 expression